Taysha Gene Therapies · pitchdeck
Taysha | IPO Presentation Deck | 66 slides
66 pages · 4 arc beats · 2 loops
Taysha | IPO Presentation Deck | 66 slides
Taysha Gene Therapies · 2020-09 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
1510152025303540455055606566
Deck intelligence map
4 coverage by narrative range · generated from this deck JSON
Narrative range 66 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Attention 5 slides 100% 5/5 slides 100% 5/5 slides · 12 hits — 0/5 slides
20% 1/5 slides — 0/5 slides
100% 5/5 slides — 0/5 slides
Interest 10 slides 100% 10/10 slides 100% 10/10 slides · 45 hits — 0/10 slides
30% 3/10 slides 30% 3/10 slides 100% 10/10 slides — 0/10 slides
Desire 15 slides 100% 15/15 slides 100% 15/15 slides · 49 hits — 0/15 slides
26.7% 4/15 slides 20% 3/15 slides 100% 15/15 slides 66.7% 10/15 slides Action 36 slides 100% 36/36 slides 100% 36/36 slides · 141 hits — 0/36 slides
8.3% 3/36 slides 13.9% 5/36 slides 100% 36/36 slides 16.7% 6/36 slides Slide inventory
66 every slide · same image gating as the playbook
01
Includes a DNA gel electrophoresis pattern as a background graphic.front_matter
Open slide detailBeat · Attention
04
The slide uses a DNA gel electrophoresis-like background graphic and a stylized logo.inspire_vision
Open slide detailBeat · Attention
06
The slide uses a four-column layout with icons and big numbers to highlight key traction metrics.show_traction
Open slide detailBeat · Interest
08
The slide uses a Gantt-style chart to represent the development status of various gene therapy programs.plan_implementation
Open slide detailBeat · Interest
09
The chart uses a staircase/waterfall visualization to show individual disease populations contributing to a total addressable market.size_opportunity
Open slide detailBeat · Interest
10
The slide uses an upward-trending arrow diagram to represent progress or acceleration.present_solution
Open slide detailBeat · Interest
11
The slide uses line charts to illustrate revenue or patient growth trajectories over time (Q1-Q15).present_solution
Open slide detailBeat · Interest
12
The slide uses a grid layout to associate individuals with their past or current corporate affiliations via logos.other
Open slide detailBeat · Interest
13
The slide highlights institutional credibility and R&D capabilities through a specific academic partnership.establish_context
Open slide detailBeat · Interest
14
The slide uses a hub-and-spoke style diagram to show how two entities contribute to a central set of activities.present_solution
Open slide detailBeat · Interest
15
The background features a faint image of a gel electrophoresis or DNA sequencing result, suggesting a biotech/genomics focus.transition
Open slide detailBeat · Interest
16
Includes a biological pathway diagram and a clinical progression timeline.frame_problem
17
The chart uses a sigmoid-like curve to show the relationship between enzyme activity and disease progression.establish_context
18
The vector uses a P2A self-cleaving linker to ensure 1:1 expression of the two genes under a single promoter.present_solution
19
The chart uses standard statistical significance markers (*, **, ****) to denote p-values against the control group.show_traction
20
The chart displays longitudinal data for five groups: Heterozygote/Vehicle, three dose levels of TSHA-101 in Knockout mice, and Knockout/Vehicle control.show_traction
21
The chart displays statistical significance markers (asterisks) comparing treatment groups to the vehicle control.show_traction
22
The slide uses a table-like structure to define the parameters of a Phase 1/2 clinical trial.plan_implementation
23
Includes a diagram of the AAV9-hCLN1 gene therapy construct.frame_problem
Open slide detailBeat · Desire
24
The chart is a standard Kaplan-Meier survival plot used in preclinical efficacy studies.show_traction
Open slide detailBeat · Desire
25
The chart compares untreated WT, Het, and KO mice against treated mice at 4, 20, and 26 weeks of age.show_traction
Open slide detailBeat · Desire
26
The slide uses a consistent icon for each pipeline entry.present_solution
Open slide detailBeat · Desire
27
The background features a DNA gel electrophoresis image, suggesting a biotech or genetic focus.transition
Open slide detailBeat · Desire
28
Includes a citation for disease reversibility research.frame_problem
29
Includes a visual spectrum diagram showing the relationship between MECP2 expression levels and clinical outcomes.frame_problem
30
The slide uses a diagram to illustrate the genetic construct (scAAV ITR, MeP426, miniMECP2, miRARE).present_solution
31
The slide uses a numbered process flow (1-5) to explain a molecular biology mechanism.present_solution
32
The slide shows immunohistochemistry images (NeuN, myc, DAPI, merge) for two experimental conditions across two mouse IDs each.illustrate_case
33
The slide displays immunofluorescence staining (NeuN, myc, DAPI, merge) across three brain regions (Thalamus, Hippocampus, Brain Stem) for two treatment groups illustrate_case
34
The chart shows survival rates over 35 weeks for various dosage groups of AAV9/MECP2 and TSHA-102.analyze_data
35
The slide compares TSHA-102 against control and other AAV9 constructs. The bottom box highlights specific adverse event rates (lesions/prolapses).show_traction
36
The chart shows survival percentages over time (weeks) for different treatment groups, with diamonds indicating vet-requested euthanasia.show_traction
38
The slide uses a consistent structure for each pipeline asset: program name, target indication, development stage, disease description, and prevalence.plan_implementation
Open slide detailBeat · Action
39
The background features a DNA gel electrophoresis image, reinforcing the genetic theme.transition
Open slide detailBeat · Action
40
The slide uses a list-based structure to detail the mechanism, clinical impact, and prevalence for each pipeline asset.present_solution
Open slide detailBeat · Action
41
The slide highlights infrastructure capabilities, specifically listing Sartorius equipment and color-coded floor plan areas.establish_context
Open slide detailBeat · Action
42
The slide includes a footnote clarifying the cash position as of June 30, 2020, adjusted for subsequent financing.show_traction
Open slide detailBeat · Action
43
The slide uses a T-shaped graphic as a visual anchor, likely referencing the company's branding or a 'T' for 'Timeline'.plan_implementation
Open slide detailBeat · Action
45
The image is a classic representation of DNA sequencing or fingerprinting, often used in biotech pitch decks to signify core proprietary technology.transition
Open slide detailBeat · Action
46
The diagram illustrates a molecular biology workflow for AAV capsid engineering.present_solution
Open slide detailBeat · Action
47
The slide highlights the potential to bypass immune responses for gene therapy redosing.present_solution
Open slide detailBeat · Action
48
Includes a disclaimer about intellectual property rights at the bottom.show_traction
Open slide detailBeat · Action
49
The slide uses a numbered process flow (1-5) to explain a biological mechanism.present_solution
Open slide detailBeat · Action
50
The slide outlines a specific R&D process (Reg1 and MiRARE) for gene therapy target identification.present_framework
Open slide detailBeat · Action
51
The slide highlights a specific 'miRARE' target panel derived from the data analysis.analyze_data
Open slide detailBeat · Action
52
The background features a gel electrophoresis image, common in biotech/genomics pitch decks.transition
Open slide detailBeat · Action
53
The chart is a box-and-whisker plot comparing age of onset, death, and last report across multiple genetic conditions, highlighting SURF1.frame_problem
Open slide detailBeat · Action
54
Includes a molecular diagram of glycogen branching and a therapeutic component breakdown (AAV9 + hGBE1 + Intrathecal delivery).frame_problem
Open slide detailBeat · Action
55
Includes a bar chart of EPM2A/EPM2B cases by country and a biological process diagram showing the transition from glycogen to Lafora bodies.frame_problem
Open slide detailBeat · Action
56
Includes a scientific diagram of glycogen branching and a bar chart showing Gys1 deficiency impact.present_solution
Open slide detailBeat · Action
57
The slide uses Kaplan-Meier survival curves and longitudinal body mass measurements to validate the therapeutic hypothesis.show_traction
Open slide detailBeat · Action
58
Includes a visual representation of MAPT mutations linked to specific FTLD-tau subtypes and a process diagram of tau aggregation.frame_problem
Open slide detailBeat · Action
59
The background image is a DNA gel electrophoresis, suggesting a biotech or genetic research context.transition
Open slide detailBeat · Action
60
Includes a visual mechanism of action diagram showing the silencing of Ube3a-ATS to restore Ube3a expression.frame_problem
Open slide detailBeat · Action
61
Includes a visual representation of the genetic mechanism (Typical vs Premutation vs Full mutation).frame_problem
Open slide detailBeat · Action
62
Includes a bar chart of clinical features and a schematic of the AAV9-shRNA mechanism.frame_problem
Open slide detailBeat · Action
63
The background features a DNA gel electrophoresis image, reinforcing the genetic focus.transition
Open slide detailBeat · Action
64
Includes a biological diagram of the synapse and a therapeutic approach summary (AAV9 + hSLC6A1 + Intrathecal delivery).frame_problem
Open slide detailBeat · Action
65
Includes a visual equation for the therapeutic approach (AAV9 + hSLC13A5 + Intrathecal delivery).frame_problem
Open slide detailBeat · Action
66
Includes a diagram of the KCNQ2 protein structure and a visual representation of a gene therapy approach (AAV9 + hKCNQ2 + Intrathecal delivery).frame_problem
Open slide detailBeat · Action